Advertisement

Topics

Under Sanpower, Can Provenge Finally Have A Happy Ending?

05:19 EDT 3 Jul 2017 | SCRIP

Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano, as Dendreon...

      

Related Stories

 

Original Article: Under Sanpower, Can Provenge Finally Have A Happy Ending?

NEXT ARTICLE

More From BioPortfolio on "Under Sanpower, Can Provenge Finally Have A Happy Ending?"

Advertisement
Quick Search
Advertisement
Advertisement